INOVIQ Ltd (ASX:IIQ)

@INOVIQLtd is collaborating with @UQ_News to develop INOVIQ’s EXO-OC screening test for the early detection of ovarian cancer. Previous studies have shown overall accuracy of 94% for detection of ovarian cancer across all stages and achieved a sensitivity of more than 90% and specificity of 96% for stage I, where women have a 5-year survival rate of over 90%. INOVIQ is planning clinical studies to support an initial US launch of the test for screening OC in asymptomatic high-risk women. To read the Channel 9 News article visit: bit.ly/41mEAD2 #IIQ #INOVIQ #OvarianCancer #EXOOC #OvarianCancerScreening #Diagnostics #UNIQUEST #Channel9 #Channel9News

@INOVIQLtd stands united in the fight against ovarian cancer this Ovarian Cancer Awareness Month. We are committed to advancing next-gen exosome diagnostics and therapeutics to detect ovarian cancer earlier and enable more effective and targeted treatment. Our goal is to bring hope, support and better outcomes to those affected by this disease. Together, we can make a difference and pave the way for a brighter, cancer-free future. #OvarianCancerAwareness #InnovationForLife #exosomes #diagnostics #therapeutics #HealthcareInnovation #ASXIIQ

@INOVIQLtd proudly supports #WorldCancerDay 🌍 We are dedicated to pioneering next-gen exosome diagnostics and therapeutics to revolutionise cancer detection and treatment. Our mission is to catch cancer earlier and create more effective therapies, bringing hope and better outcomes to those affected by cancer 🎗 Together, we can make a difference. #CancerAwareness #exosomes #diagnostics #therapeutics #IIQ #cancer #HopeForACure

On 13 December, @INOVIQLtd CEO, Dr @leearnehinch presented at Share Cafe’s Hidden Gems, ‘Sip and Learn’ webinar. To watch the presentation, go to: bit.ly/3ZzrlwV #ShareCafe #HiddenGems #SipandLearn #Webinar #SmallCap #Biotech #Therapeutics #Diagnostics #Investor #InvestorPresentation

@INOVIQLtd has successfully completed in vitro proof-of-concept (POC) for its exosome therapeutic program in breast cancer cells. Immortalised natural killer (NK) cells were engineered to continuously produce exosomes to target and kill breast cancer. CAR-NK-exosomes deliver precise anti-cancer activity, enhancing therapeutic efficacy whilst minimising off-target effects. CAR-NK-exosomes have the potential to provide a life-saving breast cancer therapeutic for patients. To read more go to: bit.ly/3DhqOIs #BreastCancer #ExosomeTherapeutics #CancerResearch #BiotechInnovation #TargetedTherapy #Immunotherapy #NKCells #ChimericAntigenReceptor #Oncology #PrecisionMedicine #CancerTreatment #Biotechnology #ASXIIQ #MedicalResearch #INOVIQ

On Friday, 6 December, @INOVIQLtd CEO, Dr. @leearnehinch was interviewed by Share Cafe about our breakthrough results for INOVIQ’s ovarian cancer test. Catch the full interview here: bit.ly/49umYb3 Don’t forget to register for the Share Cafe Hidden Gems Webinar (“Sip and Learn”) on Friday, 13 December at 12:30 PM, where Dr. Hinch will be presenting. Register for the webinar here: bit.ly/49AC2nh #OvarianCancer #CancerResearch #MedicalInnovation #Healthcare #Webinar #INOVIQ #Breakthrough #ShareCafe #HiddenGems #SmallCaps #Biotech #Diagnostics #Therapeutics

@INOVIQLtd has successfully completed disease-specificity testing for breast cancer. The test has been analytically and clinically validated to detect breast cancer across all stages (81% sensitivity and 93% specificity), key breast cancer types and subtypes, and is effective for breast cancer monitoring. This simple, accurate, and affordable blood test was developed using a widely utilised CA15-3 monoclonal antibody and INOVIQ’s SubB2M detection reagent. By specifically targeting neuCA15-3 conjugated CA15-3 produced by cancer cells, the test enhances cancer specificity and reduces the likelihood of false positives. The purpose of this study was to show the neuCA15-3 test was positive for cancer and had low false positives for non-cancer diseases and healthy. The results were negative for 97.4% of non-breast cancer samples, confirming the test specificity for breast cancer. CEO, @leearnehinch said: “The test is being developed as an LDT for the US market initially. Demonstrating the specificity of neuCA15-3 for breast cancer detection completes another component of the test validation. The next step towards commercialising the neuCA15-3 test is to transfer and optimise the test on a system compatible with high-throughput commercial diagnostic instruments.” Read more here: bit.ly/4imUxQb #INOVIQ #SubB2M #neuCA153 #BreastCancer #CancerDiagnostics #BloodTest #HealthcareInnovation #EarlyDetection #MedicalResearch #CancerResearch

@INOVIQLtd has achieved a significant milestone for its EXO-OC ovarian cancer screening test. An independent patient validation study in over 500 samples validated the test’s biomarkers and diagnostic performance, detecting ovarian cancer across all stages with overall accuracy of 94% and sensitivity of 92% at 96% specificity. In the study, exosomes were isolated from more than 500 blood samples using INOVIQ’s EXO-NET® on a fully-automated high-throughput robotic platform. Ovarian cancer biomarkers were measured using targeted mass spectrometry, a technology that can be implemented in pathology laboratories worldwide. When these high-performing EXO-NET®-isolated biomarkers were combined in cross-validated machine learning algorithms, the overall test accuracy exceeded 94%. At a test specificity set at 96%, the sensitivity was 92% for all stages of ovarian cancer and 91% for Stage I alone. The next steps are to optimize the EXO-OC test on the instrument platform and perform additional clinical validation to deliver the test in a clinical laboratory. CEO @leearnehinch said: “This biomarker panel showed outstanding performance in detecting early-stage ovarian cancer, where accurate diagnosis is most critical for improving patient outcomes. Early detection enables timely intervention, which is crucial for increasing survival rates and reducing disease progression.” To read more go to: bit.ly/3CWnMsY #INOVIQ #OvarianCancer #CancerScreening #EXOOC #EXONET #Diagnostics #HealthcareInnovation #MedicalBreakthrough #Pathology #WomensHealth #CancerResearch #EarlyDetection #Biomarkers #CancerAwareness #PrecisionMedicine

@INOVIQLtd is holding it 2024 Annual General Meeting this Thursday 28th November at 10am (AEDT). To access the Notice of Meeting go to: inoviq.com/site/pdf/3769d… Business updates will be provided by INOVIQ Chair, David Williams and CEO, Dr @leearnehinch. Should you wish to join the AGM virtually please register your attendance by clicking the following link: us02web.zoom.us/webinar/regist… #INOVIQ #IIQ #AGM2024 #Biotech #SmallCap #Diagnostics #Therapeutics

October marks Breast Cancer Awareness Month. @INOVIQLtd is developing better diagnostics and therapeutics for earlier detection and treatment of breast cancer. Show your support by wearing pink and starting important conversations with your loved ones about early detection. To help in the fight against breast cancer, visit nationalbreastcancer.org #BreastCancerAwarenessMonth #ThinkPink #EarlyDetectionSavesLives #Exosomes #Diagnostics #Therapeutics

@INOVIQLtd is pleased to welcome @memharney1 as a Non-Executive Director, effective from 1 October 2024. Mary is an experienced Non-Executive Director and Chief Executive, bringing a wealth of expertise in applied life science research, biopharmaceutical regulatory affairs, and commercialisation. To read the full announcement go to bit.ly/4d6yHgd #INOVIQ #BoardAnnouncement #Biotech #Diagnostics #Therapeutics #SmallCap

@MSTFinancial released an update note on @INOVIQLtd FY2024 results and highlights: ✔️Promega distribution agreement for EXO-NET expands global reach and expected to drive future revenues. ✔️NEURO-NET validated for isolating brain-derived exosomes in Alzheimer’s Disease. ✔️Breast & ovarian cancer detection and monitoring tests progress towards commercialisation. ✔️In vitro POC for exosome therapeutics to target and kill breast cancer. Access the full report here: bit.ly/4dDXol8 #Biotech #SmallCap #Diagnositics #Therapeutics #exosomes #MSTAccess #research #cancerresearch

@MSTFinancial released an update note on @INOVIQLtd FY2024 results and highlights: ✔️Promega distribution agreement for EXO-NET expands global reach and expected to drive future revenues. ✔️NEURO-NET validated for isolating brain-derived exosomes in Alzheimer’s Disease. ✔️Breast & ovarian cancer detection and monitoring tests progress towards commercialisation. ✔️In vitro POC for exosome therapeutics to target and kill breast cancer. Access the full report here: bit.ly/4dDXol8 #Biotech #SmallCap #Diagnositics #Therapeutics #exosomes #MSTAccess #research #CancerResearch

Daffodil Day raises awareness and much-needed funds for cancer research. At @INOVIQLtd we are committed to saving lives through diagnostics and therapeutics cancer research. To find out more visit daffodilday.com.au #DaffodilDay #CancerResearch #INOVIQ #Diagnositcs #Therapeutics

@INOVIQLtd is pleased to announce that it has further validated its NEURO-NET™ technology for isolation of brain-derived exosomes in Parkinson’s Disease (PD). Initial validation studies in PD showed: ✔️NEURO-NET™ enriches known protein biomarkers of neurodegenerative disease by 5-8 times, greatly increasing the potential for early detection of Parkinson’s. ✔️Analysis identified over 200 proteins that were decreased or increased in PD patients when compared to normal healthy individuals. To find out more go to: bit.ly/4cDqY8N #NEURONET #Parkinsons #exosomes #research #INOVIQ #validationstudy #diagnostics #therapeutics #Biotech

@mst_financial released an update note on @INOVIQLtd fuelling key FY25 priorities: • Diverse portfolio of cutting-edge technology platforms and products • Collaboration with UQ to develop exosome-based ovarian cancer screening test • SubB2M Platform delivers promising results in ovarian and breast cancers, with potential to supercharge current tests for cancer monitoring Access the full report here: bit.ly/3LZ6Pze #Biotech #SmallCap #Diagnositics #Therapeutics #Exosomes #MSTAccess #research #cancerresearch

@MSTFinancial released an update note on @INOVIQLtd fuelling key FY25 priorities: - Diverse portfolio of cutting-edge technology platforms and products - Collaboration with UQ to develop exosome-based ovarian cancer screening test - SubB2M Platform delivers promising results in ovarian and breast cancers, with potential to supercharge current tests for cancer monitoring Access the full report here: bit.ly/3LZ6Pze #Biotech #SmallCap #Diagnositics #Therapeutics #Exosomes #MSTAccess #research #CancerResearch

@MSTFinancial released an update note on @INOVIQLtd fuelling key FY25 priorities: - Diverse portfolio of cutting-edge technology platforms and products - Collaboration with UQ to develop exosome-based ovarian cancer screening test - SubB2M Platform delivers promising results in ovarian and breast cancers, with potential to supercharge current tests for cancer monitoring Access the full report here: bit.ly/3LZ6Pze #Biotech #SmallCap #Diagnositics #Therapeutics #Exosomes #MSTAccess #research #cancerresearch

@INOVIQLtd has released its June quarterly business update and Appendix 4C highlighting increasing revenue from its research tools, progress on its cancer diagnostic and therapeutic programs and a solid cash balance of $9.233m at 30 June 2024. Go to bit.ly/4d1Nf1h to read more. #INOVIQ #EXONET #Biotech #SmallCaps #Investors #CapitalRaise #Exosomes #Therapeutics #Diagnostics #CancerResearch #LifeSciences

@INOVIQLtd is pleased to announce the successful completion of the share purchase plan (SPP) with applications accepted for A$2.379m. Total funds raised of A$9.379m under SPP and placement. Go to bit.ly/3VRRO75 to read more. #INOVIQ #EXONET #Biotech #SmallCaps #Investors #CapitalRaise #Exosomes #Therapeutics #Diagnostics #CancerResearch #LifeSciences